Costs of US Prescription Opioid Epidemic Estimated at $78.5 Billion
14-Sep-2016 10:00 AM EDT
Newswise — September 14, 2016 – Prescription opioid overdose, abuse, and dependence carries high costs for American society, with an estimated total economic burden of $78.5 billion, according to a study in the October issue of Medical Care. The journal is published by Wolters Kluwer.
Health care accounts for about one-third of costs attributable to the prescription opioid epidemic, while one-fourth of costs are borne by the public sector, according to the analysis by Curtis Florence, PhD, and colleagues of the National Center for Injury Prevention and Control. They hope their findings will help in understanding the economic impact of opioid overdose, abuse, and dependence, and in guiding strategies aimed at reducing the burden of the epidemic.
"More than 40 Americans die each day from overdoses involving prescription opioids. Families and communities continue to be devastated by the epidemic of prescription opioid overdoses.” said CDC Director Tom Frieden, MD, MPH. "The rising cost of the epidemic is also a tremendous burden for the health care system."
Study Shows High Societal Costs of Opioid Epidemic Using data from a wide range of sources, the researchers estimated the "monetized burden" of prescription opioid overdose, abuse, and dependence in the United States. Costs were analyzed from a societal perspective—including direct healthcare costs, costs related to loss productivity, and costs to the criminal justice system.
Based on the latest data, nearly two million Americans met criteria for prescription opioid abuse and dependence in 2013. In the same year, there were more than 16,000 deaths from prescription opioid overdose. Both figures were substantially higher than in 2007—the most recent previous year for which comprehensive estimates were available.
Aggregate costs for prescription opioid overdose, abuse, and dependence were estimated at over $78.5 billion (in 2013 dollars). Total spending for health care and substance abuse was over $28 billion, most of which ($26 billion) was covered by insurance.
In nonfatal cases, costs for lost productivity—including reduced productive hours and lost production for incarcerated individuals—were estimated at about $20 billion. Nearly two-thirds of the total economic burden was due to health care, substance abuse treatment, and lost productivity for nonfatal cases. Fatal overdoses—including costs related to healthcare and lost productivity—accounted for $21.5 billion.
Overall, nearly one-fourth of the aggregate economic burden was funded by public sources. That included costs funded by public insurance (Medicaid, Medicare, and veterans' programs) and other government sources for substance abuse treatment.
There were also $7.7 billion in criminal justice-related costs—nearly all borne directly by state and local governments. In addition, the authors note reduced tax revenues due to opioid-related productivity losses.
Dr. Florence and colleagues point out some important limitations of the data sources and methods used to estimate costs. The study can't measure all of the societal costs of the opioid epidemic—including the impact on quality of life for opioid-dependent people, or the pain and suffering of family members who have lost loved ones due to fatal overdose.
"The costs that we can identify, however, do help increase our understanding of the impact of the epidemic," the researchers conclude. "These estimates can assist decision makers in understanding the magnitude of adverse health outcomes associated with prescription opioid use such as overdose, abuse, and dependence."
Article: "The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013" (doi: 10.1097/MLR.0000000000000625)
About Medical CareRated as one of the top ten journals in health care administration, Medical Care is devoted to all aspects of the administration and delivery of health care. This scholarly journal publishes original, peer-reviewed papers documenting the most current developments in the rapidly changing field of health care. Medical Care provides timely reports on the findings of original investigations into issues related to the research, planning, organization, financing, provision, and evaluation of health services. In addition, numerous special supplementary issues that focus on specialized topics are produced with each volume. Medical Care is the official journal of the Medical Care Section of the American Public Health Association.
About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.